Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies

Background: Patients (pts) with hematologic malignancies (HM) are thought to have suboptimal hospice utilization and receive more aggressive end of life (EOL) care than those with solid tumors (ST), including high rates of EOL chemotherapy use, ICU admissions, and inpatient deaths (Egan, Blood Adv, 2020). Barriers to equitable EOL care outcomes for pts with HM may include difficulty identifying the “terminal phase” of disease, the potential for curative stem cell transplant that lingers even after failure of multiple therapies (Odejide, JCO, 2016), and specificity of palliative needs in HM, like transfusion dependence (Leblanc, Blood, 2018), that are not met by the current hospice benefit. However, direct comparison of EOL outcomes between HM and ST in a population-based setting has not been conducted. Our objective was to compare EOL care quality measures, hospice utilization, and indicators of palliative needs between Medicare beneficiaries with HM and ST. Methods: From the linked SEER Medicare database (covering ~30% of the US population), we identified beneficiaries with common ST (breast, prostate, lung, and colorectal cancer) and HM (leukemia, myeloma, lymphoma, myelodysplastic syndrome [MDS], and myeloproliferative neoplasms [MPN]) who died between 2011-2015, and whose cause of death was cancer. We ascertained claims-based indicators of EOL care quality: hospice use before death, duration of hospice length of stay (LOS), death in an acute care hospital, receipt of (oral or parenteral) chemotherapy in the last 14 days of life (DOL), ICU admission in the last 30 DOL, Medicare spending, and inpatient days in the last 30 DOL. We also explored indicators of palliative needs: opioid use, transfusion use, and number of physician office visits in the last 30 DOL. We compared binary outcomes in multivariable robust Poisson (reporting adjusted relative risk, adj RR), counts in negative binomial, and costs in log-gamma models, reporting estimates with 95% confidence intervals (CI). Models were adjusted for age, sex, race, marital status, Medicaid co-insurance (indicator of low socio-economic status), prevalent poverty, comorbidity index, performance status indicator, calendar year, and survival from diagnosis. Results: Characteristics of the 18,185 patients with HM and 59,352 with ST are listed in Table. HM pts were, on average, older, and more likely to be male and married. HM pts were less likely than ST pts to enroll on hospice (58% vs 67%, adjusted RR 0.85,CI 0.84-0.86), had a shorter hospice LOS (median 9 vs 14 days, adj means ratio RR 0.81, CI 0.79-0.83), and were more likely to spend Discussion: To our knowledge, this is the first population-based study demonstrating that, adjusting for socio-demographic characteristics and baseline health status, pts with HM have inferior EOL care quality outcomes than those with ST. These disparities are consistent across all established EOL care quality outcomes and across all histologies, supporting the notion of a fundamental difference between EOL care in HM and ST. Furthermore, our data challenge the assumption that HM pts do not have significant palliative care needs; rather, their needs may differ from those of ST patients, and may be less easily met by the current hospice benefit (as other literature suggests). Novel care models are needed to improve EOL care for pts with HM. Download : Download high-res image (352KB) Download : Download full-size image Disclosures Panagiotou: International Consulting Associates, Inc: Other: personal fees from International Consulting Associates, Inc. outside the scope of the submitted work. LeBlanc: AstraZeneca: Research Funding; Agios, AbbVie, and Bristol Myers Squibb/Celgene: Speakers Bureau; UpToDate: Patents & Royalties; American Cancer Society, BMS, Duke University, NINR/NIH, Jazz Pharmaceuticals, Seattle Genetics: Research Funding; AbbVie, Agios, Amgen, AstraZeneca, CareVive, BMS/Celgene, Daiichi-Sankyo, Flatiron, Helsinn, Heron, Otsuka, Medtronic, Pfizer, Seattle Genetics, Welvie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Olszewski: Adaptive Biotechnologies: Research Funding; Spectrum Pharmaceuticals: Research Funding; Genentech, Inc.: Research Funding; TG Therapeutics: Research Funding.